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Abstract
Background: The cationic lipid Genzyme lipid (GL) 67 is the current "gold-standard" for in vivo
lung gene transfer. Here, we assessed, if GL67 mediated uptake of siRNAs and asODNs into airway
epithelium in vivo.
Methods: Anti-lacZ and ENaC (epithelial sodium channel) siRNA and asODN were complexed to
GL67 and administered to the mouse airway epithelium in vivo Transfection efficiency and efficacy
were assessed using real-time RT-PCR as well as through protein expression and functional studies.
In parallel in vitro experiments were carried out to select the most efficient oligonucleotides.
Results: In vitro, GL67 efficiently complexed asODNs and siRNAs, and both were stable in exhaled
breath condensate. Importantly, during in vitro selection of functional siRNA and asODN we noted
that asODNs accumulated rapidly in the nuclei of transfected cells, whereas siRNAs remained in
the cytoplasm, a pattern consistent with their presumed site of action. Following in vivo lung
transfection siRNAs were only visible in alveolar macrophages, whereas asODN also transfected
alveolar epithelial cells, but no significant uptake into conducting airway epithelial cells was seen.
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SiRNAs and asODNs targeted to β-galactosidase reduced βgal mRNA levels in the airway
epithelium of K18-lacZ mice by 30% and 60%, respectively. However, this was insufficient to reduce
protein expression. In an attempt to increase transfection efficiency of the airway epithelium, we
increased contact time of siRNA and asODN using the in vivo mouse nose model. Although highly
variable and inefficient, transfection of airway epithelium with asODN, but not siRNA, was now
seen. As asODNs more effectively transfected nasal airway epithelial cells, we assessed the effect
of asODN against ENaC, a potential therapeutic target in cystic fibrosis; no decrease in ENaC
mRNA levels or function was detected.
Conclusion: This study suggests that although siRNAs and asODNs can be developed to inhibit
gene expression in culture systems and certain organs in vivo, barriers to nucleic acid transfer in
airway epithelial cells seen with large DNA molecules may also affect the efficiency of in vivo uptake
of small nucleic acid molecules.
Background
The inhibition of gene expression mediated by antisense
oligonucleotides (asODN) has a long history. The first
asODN-based drug (Vitravene) for the treatment of
cytomegalovirus (CMV)-induced retinitis in AIDS patients
has been approved [1], and several phase I, II and III trials
for the treatment of cancer and a variety of inflammatory
conditions are currently ongoing. AsODNs have also been
considered for treatment of a variety of lung diseases
including asthma and other pulmonary inflammatory dis-
eases and have shown some efficacy in pre-clinical models
after nebulisation, intratracheal injection, intravenous or
intraperitoneal administration. Phase I trials using
asODN against the adenosine A(1) receptor have been
carried out in asthmatics and shown to be safe but phase
IIa trials did not demonstrate efficacy in patients using
inhaled steroids. [2] Effective asODN can be generated
against intronic and splice-site sequences [3,4], implying
that asODN function mainly in the nucleus, where they
bind to mRNA target sequence specifically by forming
Watson-Crick base pairs. The mRNA/asODN hybrid is
subsequently recognised by RNase H, which leads to deg-
radation of the mRNA target.
More recently RNA interference (RNAi), using short (<30
bp) double-stranded RNA molecules termed siRNAs, has
emerged as an alternative gene silencing strategy. RNAi
was first identified in plants and invertebrates, but more
recently also in mammalian cells. Since the studies in
mammalian cells [5,6] a large number of publications
now document the use of RNAi in cell culture-based sys-
tems and the power of RNAi for drug validation and stud-
ies of enzyme pathways is well recognized. The use of
RNAi as a therapeutic approach is in its infancy, but sev-
eral organs, including liver, eye, lung, brain, skeletal mus-
cle, as well as tumours, have been targeted successfully in
vivo.
Antisense or RNAi-mediated gene silencing may provide
novel opportunities for the treatment of cystic fibrosis
(CF). CF is caused by mutations in the cystic fibrosis trans-
membrane conductance regulator gene (CFTR) and affects
many organs, but most morbidity and mortality relates to
chronic inflammation and bacterial colonisation of the
lung. The CFTR gene encodes a chloride channel in the
apical membrane of epithelial cells, and in CF patients
chloride secretion through CFTR is reduced or absent.
This, coupled with increased sodium absorption through
the epithelial sodium channel (ENaC), leads to abnormal
water transport across the epithelium and accumulation
of sticky, dehydrated mucus, which in turn leads to
chronic bacterial colonisation and inflammation
(reviewed in [7]). Similar to CFTR, ENaC is expressed in
airway surface epithelium and glands [8]. Normally CFTR
inhibits ENaC-mediated sodium transport, although the
mechanism is not completely understood [9,10]. In CF
this inhibition is lost, resulting in increased sodium and
water absorption. Down-regulation of ENaC expression,
or inhibition of its function, may therefore attenuate CF
lung disease. The latter has proved difficult [11] because
of the short half-life of amiloride, and potential renal side
effects of longer acting inhibitors. With regards to the
former, ENaC consists of 3 separate subunits (α, β and γ).
Jain et al generated asODN against all three subunits, and
demonstrated that only asODN against the α subunit sig-
nificantly decreased the density of ENaC channels [12].
Transfection of differentiated airway epithelial cells with
plasmid DNA (pDNA), which is generally >5000 bp, is
inefficient, and the extra- and intracellular barriers to air-
way gene transfer have been identified over the last decade
(reviewed in [13]). Here, we assessed, whether smaller
nucleic acids such as asODNs (20 bases) or siRNA (20–22
base pairs) can more readily overcome these barriers, and
thereby provide an alternative approach for the treatment
of CF lung disease.Respiratory Research 2006, 7:26 http://respiratory-research.com/content/7/1/26
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Material and methods
SiRNA, asODN and in vitro assessment of lipid 
complexation
The asDNA used in this study were designed using a pro-
prietary algorithm (GlaxoSmithKline, Stevenage, UK).
The oligonucleotides were 'gapmers' and consisted of 2'O-
methyl RNA (5 residues), phosporothioate DNA (10 resi-
dues), 2'O-methyl RNA (5 residues), and were synthesised
by Proligo (Hamburg, Germany) [14]. Synthetic siRNAs
(CAT, GFP, LacZ) were synthesized by Xeragon using 29-
O-(tri-isopropyl) silyloxymethyl chemistry (Qiagen Inc.
Germantown MD, USA) as previously described [5]. Syn-
thetic siRNAs corresponding to ENaC were obtained from
Dharmacon Inc (Chicago, IL, USA).
SiRNA and asODN (1.6 mg/ml = 4.8 mM) were com-
plexed to Genzyme Lipid 67 (GL67) at different molar
ratios (lipid:DNA) in a total volume of 100 ul as previ-
ously described [13]. Following incubation, 8 µg siRNA
and asDNA from each reaction were separated on an aga-
rose gel (0.4%) to resolve lipid-complexed and free nucle-
otides. Controls included a standard plasmid (6 kb)
complexed in a similar manner. At least two independent
reactions were carried out for each condition and repre-
sentative images are shown. Particle size was determined
by dymanmic laser light scatter using a Coulter N4SD sub-
micron particle analyser (Hialeah, USA).
Stability in exhaled breath condensate (EBC)
CF patients were recruited through the Adult Cystic Fibro-
sis Service at the Western General Hospital in Edinburgh.
Non-CF control subjects were recruited from staff at the
Western General Hospital. Written informed consent was
obtained and the study was approved by the Lothian
Health Ethics Committee. Prior to collection of EBC, sub-
jects rinsed their mouths with water. Subjects then
breathed through a Jaeger Ecoscreen EBC collection device
(Jaeger, Hoechberg, Germany) for 5 minutes. This allows
subjects to perform tidal breathing through a two-way
valve mechanism while trapping saliva. 500–1000 µl of
EBC were collected from each individual. To determine
the stability of asDNA or siRNA in fresh EBC, equal vol-
umes of nucleic acid (diluted to 500 ng/µl in nuclease-free
H20) and EBC from either a CF patients (n = 2) or healthy
individuals (n = 2) were incubated together for 1, 5, 30
and 60 minutes at 37°C. As positive and negative con-
trols, each nucleic acid was incubated with either nucle-
ase-free H20, 200 ng RNase A (QIAGEN) or 2 units DNase
1 (Sigma), as appropriate, for 1, 5, 30 and 60 minutes at
37°C. After incubation, the samples were placed on ice
and immediately characterised using the Agilent 2100
Bioanalyser microfluidics system (Agilent Technologies
UK Ltd, Stockport, UK). For this, 1 µl of denatured sample
was loaded onto a primed RNA 6000 chip and the integ-
rity of each nucleic acid was determined from the digital
output data.
Cell culture based transfection
For cell culture based pre-screening of siRNAs approxi-
mately 2 × 105 NIH-3T3 cells stably expressing β-galactos-
idase (generated through retroviral transduction of an
ecotropic retroviral vector carrying LacZ and G418 slec-
tion for neomycin resistance) were transfected with 2 µg
of siRNA complexed with 10 µg Lipofectamine 2000 (Life
Technologies, Gaithersburg, MD) in 12-well plates.
SiRNA-lipid complexes were formed in unsupplemented
medium (DMEM), and added directly to cells after
approximately 15 minutes. Four hours after addition of
the siRNA-lipoplex, DMEM plus 20% foetal bovine serum
was added. Cells were harvested 72–96 hours after trans-
fection and assayed for β-galactosidase protein expression
For cell culture based pre-screening of asDNA, NIH-3T3-
lacZ cells were plated at 2 × 104 cells per well in a 96-well
plate, 18 hours prior to transfection. Liposome complexes
were made up as follows: for each well, 10 µl of 10× final
concentration asDNA (100 or 200 nM) were diluted in
OptiMem (Invitrogen, Paisley, UK) from a 100 M stock in
water. This was mixed with 5 µg Lipofectamine 2000 (Inv-
itrogen, UK) in 10 µl OptiMem, and incubated for 15 min
at room temperature. Complexes were then diluted to a
total volume of 100 µl in OptiMem and added directly to
cells after washing with OptiMem. Forty-eight hours after
transfection, cells were lysed and β-gal protein and total
protein assayed using the β-gal reporter kit (Roche, Wel-
wyn, UK) and the Coomassie Plus Protein Assay kit (Per-
Bio, Cramlington, UK) according to manufacturer's rec-
ommendations. M1 cells (murine kidney epithelium)
(ATCC) were grown to 70% confluency in 6-well-plates
and transfected with ENaC siRNA or asDNA (100 nM or
200 nM) complexed to Lipofectamine 2000 (5 µg lipid/
ml,) as described above. Forty-eight hours after transfec-
tion cells were harvested and total RNA prepared and
quantitative RT-PCR carried out as described below.
To determine transfection efficiency and intracellular dis-
tribution, semi-confluent M1 cells were transfected in 8-
well chamber slides with lipid-complexed FITC-labelled
siRNA, asDNA (final concentration 100 nM), lipid only or
left untransfected (VWR, Leics, UK). Transfection reagents
and volumes were scaled down according to surface area
(well in 6-well plate: 9.4 cm2, well in 8-well chamber slide
0.32 cm2). At different time-points after transfection (1,
15, 30, 60 min, 2, 4, 6, 8, 18 and 24 hours) cells were
washed in PBS, fixed in 4% paraformaldehyde for 10 min,
washed again in PBS, stained with DAPI (1 µg/ml) for 15
min and mounted with Vectashield (Invitrogen, Paisley,
UK). Confocal microscopy was carried at an original mag-
nification of 40×. Two independent experiments were car-Respiratory Research 2006, 7:26 http://respiratory-research.com/content/7/1/26
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ried out with n = 2 wells per condition. A minimum of 3
fields of view were analysed per well. Representative
images are shown.
In vivo transfection of lungs
All animal studies were approved by the UK Home Office
and Imperial College London. Flourescently (FITC)-
labelled asODN or siRNA (160 µg/mouse in 100 µl, the
maximum total volume allowed for lung instillations)
were complexed to GL67 at a 0.25:1 molar ratio
(lipid:DNA) controls received lipid only. BALB/C mice
(female 6–10 weeks, n = 3/group) were anaesthetised with
metophane (Medical Developments Australia Pty Ltd,
Springvale, Australia) and the liposome complexes were
placed as a single bolus into the nasal cavity and the solu-
tion rapidly sniffed into the lungs. One and 24 hours after
transfection animals were culled, the trachea exposed and
the lungs inflated with 4% paraformaldehyde (pH 7.3)
using a catheter (20 gauge, Ohmeda, Sweden) inserted
into the trachea. The lungs were than removed en bloc and
placed into 4% paraformaldehyde for a further 12–18
hours. The tissues were processed and paraffin-embedded
using standard procedures and 5 µm sections cut (at least
5/mouse approximately 50 µm apart). Sections were
counter stained with DAPI (1 µg/ml) and mounted with
Vectashield (Invitrogen). Biodistribution was determined
using confocal microscopy with an optical thickness of 1
µm (60× objective). A total of 6 individual images from
different regions of the lung per animal/section were ana-
lysed and representative images are shown.
For transfection of K18-lacZ mice, siRNA or asDNA were
complexed to GL67 and mice were transfected as
described above (40 and 160 µg/mouse, respectively). At
indicated time-points after transfection lungs were har-
vested, split in half and processed for βgal mRNA (see
below) and protein quantification. The 72 hours control
group in the asDNA mRNA graph is missing for technical
reasons. For the βgal protein quantification lungs were
homogenised in 500 µl Universal Lysis Buffer (Roche),
freeze/thawed three times, spun at 10,000 gav for 10 min
and supernatant was frozen for analysis. βgal protein
expression was quantified in lung homogenates using the
luminescent  βgal Reporter System 3 (BD Biosciences
Clontech, Palo Alto, USA) according to manufacturer's
recommendations. Total protein was quantified using the
DC Protein Assay Kit (BioRad, Herts, UK) according to
manufacturer's recommendations and data expressed as
pg βgal/mg total protein. Two independent experiments
were carried out for each condition.
In vivo transfection of nose and PD measurements
Fluorescently (FITC)-labelled asDNA or siRNA were com-
plexed to GL67 (80 µg/mouse in 100 µl total volume).
Mice (BALB/C, female 6–10 weeks) were anaesthetised
[one part Hypnorm (Janssen Animal Health, Oxford, UK),
one part Hypnovel (Roche, Welwyn Garden City, UK),
Stability of siRNA and asODN in exhaled breath condensate  (EBC) Figure 2
Stability of siRNA and asODN in exhaled breath con-
densate (EBC). siRNA (A) or asODN (B) were incubated 
for one to 60 min in water or EBC from CF and non-CF indi-
viduals. Oligonucleotide integrity was assessed using the Agi-
lent Bioanalyser 2100 system. In control reactions siRNA and 
asODN were incubated with RNase A and DNase I, respec-
tively, for one to 60 min. Arrowhead indicates oligonucle-
otides. Asterisk indicates lane marker.
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Gel retardation of Genzyme lipid 67 (GL67)-complexed plas- mid DNA, siRNA and asODN Figure 1
Gel retardation of Genzyme lipid 67 (GL67)-com-
plexed plasmid DNA, siRNA and asODN . Plasmid 
DNA (A), siRNA (B) or asODN (C) were complexed to 
GL67 at different lipid:nucleic acid molar ratios and com-
plexes were separated on agarose gels. (Lane 1 = 0.25:1, 2 = 
0.5:1, 3 = 0.75:1, 4 = 1:1 lipid: nucleic acid molar ratios, 5 = 
no lipid control, 6 = empty well).
A.
1234 56
B.
1234 56
C.
1234 56Respiratory Research 2006, 7:26 http://respiratory-research.com/content/7/1/26
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and two parts water for injection (10 ml/kg)] and placed
onto heated boards in the supine position. A fine tip cath-
eter was inserted 5 mm into the nasal cavity and the lipo-
some formulation was slowly perfused (1.3 µl/min) over
75 min using a peristaltic pump. During the procedures
the animals were placed at an angle (approximately 45°
head down) to prevent aspiration. One or twenty-four
hours after transfection animals were culled, the nasal
septum removed and fixed over-night in 4% paraformal-
dehyde. The tissues were processed and paraffin-embed-
ded using standard procedures and 5 µm sections cut (at
least 5/mouse approximately 50 µm apart). Sections were
counter stained with DAPI (1 µg/ml) and mounted with
Vectashield (Molecular Probes). Distribution was deter-
Distribution of FITC-labelled asODN in M1 cells in vitro Figure 3
Distribution of FITC-labelled asODN in M1 cells in vitro. M1 cells were transfected with Lipofectamine 2000-com-
plexed FITC-labelled asODN. At indicated time-points after transfection cells were harvested and processed for confocal 
microscopy. Nuclei were stained with DAPI and are shown in blue (left panel), FITC signal is shown in green (right panel). A 
and B show biodistribution 30 min after transfection, C and D show biodistribution 24 hrs after transfection.
A. B.
C. D.Respiratory Research 2006, 7:26 http://respiratory-research.com/content/7/1/26
Page 6 of 15
(page number not for citation purposes)
mined using confocal microscopy with an optical thick-
ness of 1 µm (60× objective). A total of 6 individual
images from different regions of the septum per animal
were analysed and representative images are shown.
For transfection with ENaC asODN5, the asODN was
complexed to GL67 and the mouse transfected as
described above. Twenty-four, 48 and 72 hours after trans-
fection nasal potential difference (PD) was measured as
Distribution of FITC-labelled siRNA in M1 cells in vitro Figure 4
Distribution of FITC-labelled siRNA in M1 cells in vitro. M1 cells were transfected with Lipofectamine 2000-complexed 
FITC-labelled siRNA. At indicated time-points after transfection cells were harvested and processed for confocal microscopy. 
Nuclei were stained with DAPI and are shown in blue (left panel), FITC signal is shown in green (right panel). A and B show 
biodistribution 30 min after transfection, C and D show biodistribution 24 hrs after transfection.
C. D.
A. B.Respiratory Research 2006, 7:26 http://respiratory-research.com/content/7/1/26
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described below, after which the animal was culled and
the nasal septum removed for RNA extraction and mRNA
quantification.
PD measurements were carried out as previously
described [16]. In brief, a fine, double-lumen polyethyl-
ene catheter was inserted into the nose. One lumen con-
veyed perfusate via a peristaltic pump (Pharmacia,
Cambridge, UK) at a rate of 21 µl/min, and the other
served as an exploring electrode connected via a calomel
electrode (Russell pH Ltd., Auchtermuchty, Scotland, UK)
to a handheld computer (Psion, London, UK) containing
a low-pass signal-averaging filter with a time constant of
0.5 s (Logan Research Ltd., Sussex, UK). A reference elec-
trode was placed subcutaneously in the flank of the
mouse and was similarly connected to the computer. The
circuit was validated with a measurement of buccal PD
prior to insertion of the catheter, acceptable values being
10 to 20 mV. After recording of baseline PD, animals were
perfused with a buffer containing amiloride to inhibit
sodium absorption via ENaC channels.
RNA extraction and quantitative RT-PCR
For RNA extraction tissue samples were immediately sub-
merged in RNAlater (Ambion, Huntingdon, UK) after har-
vesting and stored at or below 4°C until further analysis.
Cells were immediately submerged in RLT buffer (Qiagen,
Germany) and stored at -80°C. Tissue samples were
homogenized in RLT buffer and cell samples were passed
through a QiaShredder (Qiagen Ltd, Crawley UK) prior to
extraction of total RNA using the RNeasy mini protocol
(Qiagen). Levels of mRNA were quantified by real-time
quantitative multiplex TaqMan RT-PCR using the ABI
Prism 7700 Sequence Detection System and Sequence
Detector v1.6.3 software (Applied Biosystems, War-
rington, Cheshire, UK). The oligonucleotide primer and
fluorogenic probe sequences were designed using Primer
Express Software version 1.5 (Applied Biosystems). LacZ
mRNA was quantified using forward LacZ primer (5' ATC
AGG ATA TGT GGC GGA TGA 3'), reverse LacZ primer (5'
CTG ATT TGT GTA GTC GGT TTA TGC A 3'), and fluoro-
genic LacZ probe (5' FAM- CGG CAT TTT CCG TGA CGT
CTC GTT -TAMRA 3'). ENaC mRNA was quantified using
Distribution of FITC-labelled siRNA and asODN in mouse lung Figure 5
Distribution of FITC-labelled siRNA and asODN in mouse lung. FITC-labelled asODN (a) and siRNA (b) (160 µg/
mouse) were complexed to GL67 and "sniffed" into mouse lung. One or 24 hours after transfection the lungs were paraffin-
embedded and processed for confocal microscopy. Nuclei are shown in blue, FITC signal is shown in green. Arrow indicates 
alveolar macrophage.
A. B.Respiratory Research 2006, 7:26 http://respiratory-research.com/content/7/1/26
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forward ENaC primer (5' GAC CTC CAT CAG TAT GAG
AAA GGA A 3'), reverse ENaC primer (5' GAC ATC GCT
GCC ATT CTC AGT 3'), and fluorogenic ENaC probe (5'
VIC- CCT GGA CAG CCT CGG AGG CAA CTA -TAMRA
3'). mCFTR was quantified using forward mCFTR primer
(5' TCG TGA TCA CAT CAG AAA TTA TTG ATA AT 3'),
reverse mCFTR primer (5' CCA CCT CTC TCA AGT TTT
CAA TCA T 3') and fluorogenic mCFTR probe (5' FAM-
CGC TCA TTC CCA ACA ATA TGC CTT AAC AGA ATA -
TAMRA 3').
RNA was reverse transcribed with TaqMan RT reagents
(Applied Biosystems). The RT-reaction mix (5 µl) con-
sisted of 1X TaqMan RT buffer, 5.5 mM MgCl2, 500 µM
each dNTP, 0.4 U/µl RNase inhibitor, 1.25 U/µl Multi-
Scribe Reverse Transcriptase, 0.4 µM of LacZ or ENaC
reverse primer, 0.4 µM of rRNA reverse primer and
approximately 50 or 100 ng total RNA for ENaC or LacZ
quantification, respectively. Reactions were incubated at
48°C for 30 min followed by 95°C for 5 min. Subse-
quently, triplicate 25-µl PCRs were performed for each
sample. Each 25-µl reaction consisted of 1X TaqMan Uni-
versal PCR Mastermix (Applied Biosystems), 300 nM for-
ward primer, 300 nM reverse primer, 100 nM probe, and
5  µl reverse-transcribed template. Reactions were incu-
bated at 50°C for 2 min and then 95°C for 10 min fol-
Table 1: siRNA and asDNA used in this study
Name Sequence (from 5' to 3')
Antisense oligonucleotides
FITC-asDNA UACGATGCTGCTAGCUAGUA
LacZ as 1 AUCAUCATTAAAGCGAGUGG
LacZ as 2 AUGGAAACCGTCGATAUUCA
LacZ as 3 GGAAGGATCGACAGAUUUGA
LacZ as 4 AACAGGTATTCGCTGGUCAC
LacZ as 5 CCAUGCCGTGGGTTTCAAUA
Control 1 UACGATGCTGCTAGCUGUAC
Control 2 UCGAUGTAGCTAGCTAUGUC
αENaC asODN 1 GAAUGGAGGAGGATGUCAGA
αENaC asODN 2 ACCGUGGATGGTGGTAUUGU
αENaC asODN 3 GUUGAAACGACAGGTAAAGA
αENaC asODN 4 GUGGAAGATGTGCTGAAGUG
αENaC asODN 5 UUCUGGTTGCACAGTUGGAA
Synthetic small interfering RNAs
LacZ siRNA 1 Sense Z1
Antisense Z1
5'PO4 r(acc cug gcg uua ccc aac uua a)3'OH
5'PO4 r(aag uug ggu aac gcc agg guu u)3'OH
LacZ siRNA 2 Sense Z2
Antisense Z2
5'PO4 r(gcu ggc ugg agu gcg auc uu)3'OH
5'PO4 r(gau cgc acu cca gcc agc uu)3'OH
LacZ siRNA 3 Sense Z3
Antisense Z3
5'PO4r(ccu auc cca uua cgg uca auc c)3'OH
5'PO4r(auu gac cgu aau ggg aua gg)3'OH
LacZ siRNA 4 Sense Z4
Antisense Z4
5'PO4 r(ccg acu aca caa auc agc gau u)3'OH
5'PO4 r(ucg cug auu ugu gua guc ggu u)3'OH
LacZ siRNA 5 Sense Z5
Antisense Z5
5'PO4 r(guu cag aug ugc ggc gag uu)3'OH3
5'PO4 r(cuc gcc gca cau cug aac uu)3'OH
LacZ siRNA 6 Sense Z6
Antisense Z6
5'PO4 r(cuu uaa cgc cgu gcg cug uu)3'OH
5'PO4 r(cag cgc acg gcg uua aag uu)3'OH
LacZ siRNA 7 Sense Z7
Antisense Z7
5'PO4 r(gcc aau auu gaa acc cac gg)3'OH
5'PO4 r(gug ggu uuc aau auu ggc uu)3'OH
LacZ siRNA 8 Sense Z8
Antisense Z8
5'PO4 r(cug ugc cga aau ggu cca uca a)3'OH
5'PO4 r(gau gga cca uuu cgg cac agc c)3'OH
LacZ siRNA 9 Sense Z9
Antisense Z9
5'PO4 r(gca aaa cac cag cag cag uu)3'OH
5'PO4 r(cug cug cug gug uuu ugc uu)3'OH
LacZ siRNA 10 Sense Z10
Antisense Z10
5'PO4 r(gug acc agc gaa uac cug uu)3'OH
5'PO4 r(cag gua uuc gcu ggu cac uu)3'OH
Control siRNAs
CAT sense
antisense
5'PO4 r(gag uga aua cca cga cga uuu c) 3' OH
5'PO4 r(aau cgu cgu ggu auu cac ucc a) 3' OH
FITC-CAT sense
antisense
5'PO4 r(gag uga aua cca cga cga uuu c) 3' 
Fluorescein
5'PO4 r(aau cgu cgu ggu auu cac ucc a) 3' OH
GFP sense
Antisense
5'PO4 r(gca agc uga ccc uga agu uca u) 3' OH
5'PO4 r(gaa cuu cag ggu cag cuu gcc g) 3' OHRespiratory Research 2006, 7:26 http://respiratory-research.com/content/7/1/26
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lowed by 40 cycles of 95°C for 15 s and 60°C for 1 min.
Controls included no-template and no-reverse tran-
scriptase reactions in which total RNA or MultiScribe
reverse transcriptase and RNase inhibitor were omitted
from the reverse transcriptase reaction, respectively. Rela-
tive levels of ENaC- or LacZ-specific mRNA were deter-
mined using the ∆∆CT method [17]. In this study the
amount of target LacZ or ENaC was normalized to ENaC
or murine CFTR, respectively (endogenous reference) and
expressed relative to an arbitrary calibrator sample that
was used throughout the study. The calibrators used were
RNA derived from a K18-LacZ transgenic mouse lung for
LacZ quantification and naïve mouse lung for ENaC
quantification.
Statistical Analysis
Values are expressed as the mean ± SEM for convenience
or dot plots plus mean. n refers to the number of animals
or tissue culture samples used. Data were compared using
ANOVA plus post hoc analysis or independent sample t-
test where appropriate or paired sample test for PD meas-
urements. The null hypothesis was rejected at p < 0.05.
Results
Assessment of the physical characteristics of GL67-
complexed small nucleic acids
The characteristics of plasmid DNA(pDNA)-Genzyme
Lipid 67 (GL67) complexes have been described [18]. To
compare these with small nucleic acid molecules asOD-
NAs and siRNAs we generated lipoplexes [18] using a
range of lipid:nucleotide molar ratios (0.25:1 to 1:1). Aga-
rose gels (Figure 1) showed that at the 0.25:1 ratio, which
is the most efficient ratio for lung gene transfer [18],
approximately 75% of the nucleotides (siRNA, asODN or
pDNA) were incorporated within lipoplexes In all cases,
increasing the lipid:nucleotide ratio further increased the
amount of complexed nucleic acid. Light scatter analysis
was used to determine the size of the lipoplexes, which
were 294 ± 17, 369 ± 24 and 682 ± 235 nm for siRNA,
asODN and pDNA, respectively at the 0.25:1 molar ratio
and did not change at the 0.75:1 ratio (data not shown, n
= 4/group in 2 independent experiments).
Stability of siRNAs and asODNs following exposure 
exhaled breath condensate (EBC)
Nucleic acids are prone to nuclease degradation. The sta-
bility of phosphorothioated asODN, in a variety of body
fluids is well described, but neither the stability of
asODNs or siRNAs has been studied in airway surface liq-
uid (ASL), a potential barrier to transfection of the airway
epithelium. ASL is difficult to collect, and we therefore
used exhaled breath condensate (EBC) as a surrogate.
Uncomplexed siRNA and asDNA nucleic acids were incu-
bated in CF (n = 2) and non-CF (n = 2) EBC samples, or
water, for 1–60 min. No evidence of nucleic acid degrada-
tion was observed (Figure 2). In control experiments siR-
NAs or asODNs were incubated with either RNase A or
βgal mRNA in vivo lung transfection of K18-lacZ with lacZ  asODN Figure 7
βgal mRNA in vivo lung transfection of K18-lacZ with 
lacZ asODN. LacZ asODN (as4) or a control ODN was 
complexed to GL67 (160 µg/mouse), placed as a bolus (100 
µl) onto the nostrils of anaesthetised mice and "sniffed" into 
the lung. Forty-eight to 96 hours after transfection the lungs 
were harvested and β-gal mRNA was quantified. Each dia-
mond represents an individual animal. The mean per group is 
indicated as a horizontal bar. * indicates p < 0.05 when com-
pared to control group.
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In vivo lung transfection of K18-lacZ with lacZ siRNA. 
LacZ siRNA (Z7) or control siRNA was complexed to GL67 
(40 µg/mouse), placed as a bolus (100 µl) onto the nostrils of 
anaesthetised mice and "sniffed" into the lung. Forty-eight 
hours after transfection the lungs were harvested and βgal 
mRNA (A) and protein expression (B) were quantified. Each 
diamond represents an individual animal. The mean per 
group is indicated as a horizontal bar. * indicates p < 0.05 
when compared to control group.
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DNase I, respectively, for 1 to 60 min. In both cases com-
plete degradation of the siRNA and asODN was seen (Fig-
ure 2).
Intracellular location of siRNAs and asODNs in vitro
M1 cells, a murine kidney cell line, express ENaC [19] and
are, therefore, suitable for screening anti-ENaC siRNA and
asODN sequences (see below). However, these cells have
not been routinely used for transfection experiments.
Here, we first determined transfection efficiency using
FITC-labelled siRNAs and asODNs complexed to Lipo-
fectamine 2000, one of the most efficient liposomes for in
vitro nucleic acid gene transfer. AsODNs rapidly (as early
as 30 min after transfection, Figure 3A+B) accumulated in
the nucleus of transfected cells, whereas siRNA was only
detectable in the cytoplasm (Figure 4A–D, n = 3 wells/
time point). Twenty-four hours after transfection approx-
imately 80–90% of cells were transfected with either mol-
ecule (Figure 3C and 3D) and the overall distribution
remained unchanged, with asODNs accumulating in the
nuclei and siRNA in the cytoplasm. In control experi-
ments we also transfected cells with double-stranded
DNA oligonucleotides (dsODN); nuclear accumulation
was similar to single-stranded asODN (data not shown).
Thus interestingly, the intracellular localisation of siRNA
and ODN appear to be consistent with their presumed
sites of action.
Distribution of siRNA- and asODN in the murine lung in 
vivo
Genzyme Lipid (GL67) has been optimised for gene trans-
fer to the airway epithelium and has been used in CF gene
therapy trials [20,21] and was, therefore, an obvious
choice for delivering asODN and siRNA to the airways.
We administered FITC-labelled siRNA and asODN (160
µg/mouse) complexed to GL67 to the mouse lung using a
standard intranasal instillation protocol to determine dis-
tribution (n = 3/group). Interestingly, 24 hours after trans-
fection the distribution of the two molecules was very
different. Abundant asODN signal was visible in the cyto-
plasm of alveolar epithelial cells (Figure 5A), with only
sporadic signal in the airway epithelium whereas siRNA
could only be detected in alveolar macrophages (Figure
5B). For both siRNA and asODN, there was no difference
in staining pattern one hour (data not shown) and 24
hours after transfection.
Efficacy of siRNA- and asODN-mediated gene silencing in 
the murine lung in vivo
Although FITC-labelled nucleic acids is an informative
way to assess bio-distribution, tracking low levels of trans-
fection in airway epithelial cells may have been below the
detection limit of this assay. To address this potential
problem, we studied K18-lacZ transgenic mice, which
express β-galactosidase (β-gal) in airway epithelial cells
(20) as a functional read-out of transfection efficiency. We
first designed and tested 10 lacZ siRNA and 5 lac Z asODN
(see Table 1 for sequences) in NIH-3T3 cells stably
expressing LacZ. Three out of 10 lacZ siRNA reduced βgal
expression by >50% relative to control levels (Z4: 919 ±
315 pg β-gal/mg protein; Z5: 1135 ± 194 pg β-gal/mg pro-
tein, Z7: 976 ± 310 pg β-gal/mg protein, control siRNAs:
CAT: 2791 ± 306 pg β-gal/mg protein, GFP: 2896 ± 385 pg
β-gal/mg protein); Z7 was chosen for further in vivo stud-
ies. All five lacZ asODN reduced expression between 40–
60% relative to control asODN assayed 48 hrs after trans-
fection. The most effective asODN (as4) reduced lacZ
expression from 3133+/-346 pg βgal/mg protein in con-
trols to 1044+/-142 pg/mg in asODN treated cells (p <
0.05) and this asODN was used in subsequent in vivo
experiments.
The lacZ (Z7) siRNA was complexed to GL67 and admin-
istered by intranasal instillation to the mouse lung. Forty-
eight hours later lungs were harvested, divided into two
parts and used for mRNA quantification (quantitative RT-
PCR) and βgal protein quantification (Figure 6). In ani-
mals treated with lacZ siRNA βgal mRNA was reduced by
approximately 33% when compared to controls (lacZ
siRNA: 0.58 ± 0.07, controls siRNA: 0.87 ± 0.07 relative
lacZ mRNA expression, n = 12–14/group, p < 0.01). How-
ever, there was no significant change in βgal protein
expression.
βgal protein after in vivo lung transfection of K18-lacZ with  lacZ asODN Figure 8
βgal protein after in vivo lung transfection of K18-
lacZ with lacZ asODN. LacZ asODN (as4) or a control 
ODN was complexed to GL67 (160 µg/mouse), placed as a 
bolus (100 µl) onto the nostrils of anaesthetised mice and 
"sniffed" into the lung. Forty-eight to 96 hours after transfec-
tion the lungs were harvested β-gal protein expression was 
quantified. Each diamond represents an individual animal. The 
mean per group is indicated as a horizontal bar. * indicates p 
< 0.05 when compared to control group.
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LacZ asODN was also complexed to GL67 and adminis-
tered by intranasal instillation. Gene expression was ana-
lysed 48, 72 and 96 hours after administration. There was
no decrease in lacZ mRNA at 48 hours, but 72 and 96
hours after transfection lacZ mRNA was significantly (p <
0.01) reduced by >60% (Figure 7) when compared to con-
trols (n = 6–9/group). Similar to the siRNA there was no
decrease in lacZ protein expression at any time-point stud-
ied (Figure 8). It is worth noting that these studies were
only powered (80% power at p < 0.05) to detect a decrease
in βgal protein expression of at least 60%.
Distribution of asODN and siRNA in the murine nose in 
vivo
Inefficient transfection of airway epithelial cells may be a
key limiting factor in achieving meaningful levels of
down-regulation of gene expression in vivo. The short con-
tact time between airway epithelial cells and the adminis-
tered complexes, as well as their pooling in alveolar region
following the intranasal method likely contributes to this
inefficiency. The murine nasal epithelium has a cell com-
position similar to that of the lower airways, and allows
increased contact time by slow perfusion of the complexes
directly onto the nasal epithelium via a catheter. This
route of administration also allowed us to make func-
tional measurements of ENaC silencing, via transepithe-
lial potential difference measurements which can easily be
undertaken in the murine nose.
To assess uptake efficiency in this region we perfused ani-
mals with FITC-labelled asODN or siRNAs complexed to
GL67 (80 µg/mouse) and harvested tissues one or 24
Distribution of FITC-labelled asODN in the mouse nose in vivo Figure 9
Distribution of FITC-labelled asODN in the mouse nose in vivo. FITC-labelled asODN (80 µg/mouse) were com-
plexed with GL67 and perfused into the nasal cavity. Twenty-four hours later the nasal septum was extracted, paraffin-embed-
ded and processed for confocal microscopy. Nuclei are shown in blue, FITC signal is shown in green. Arrows indicate the 
surface epithelium. A and B are images from two different animals showing the highest (A) and lowest (B) levels of uptake seen.
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hours after delivery (n = 6). No uptake of siRNA into nasal
epithelial cells was seen at any time-point (data not
shown) and, therefore, no further studies were under-
taken with siRNA. For asODN the efficiency of uptake var-
ied greatly from animal to animal. Figure 9A+B shows
representative images from two treated animals covering
the range of uptake seen. In general efficiency of uptake
was low, with most animals (5 out of 6 mice) having only
a few (<10/section) FITC-positive cells. There was no dif-
ference in staining pattern one hour (data not shown) and
24 hours after transfection.
Efficacy of anti ENaC asODN in the murine nose in vivo
To assess the efficacy of asODN against ENaC we first
designed five ENaC asODN against the murine α subunit
(αENaC asODN) and transfected into M1 cells using
standard transfection conditions. Forty-eight hours after
transfection cells were harvested and αENaC mRNA was
quantified (Figure 10). The relative degree of αENaC
mRNA reduction varied with asODNs and ranged from 5
to 60% (n = 6/group). Subsequent in vivo experiments
were carried out using αENaC asODN 5.
Transepithelial potential difference measurements (PD)
have been widely used to measure ion transport across
murine nasal epithelium (21). A decrease in ENaC func-
tion would result in (a) a drop in baseline PD, because
sodium transport is the main component of basal ion
transport in the nasal mucosa and (b) a reduced effect of
the ENaC blocker amiloride. We complexed αENaC
asODN4 to GL67 (80 µg/mouse) and perfused these com-
plexes into the mouse nose over 75 min. Twenty-four, 48
or 72 hours after administration basal PD and the effect of
amiloride were measured in individual cohorts of animals
(n = 10/group). After PD measurements all animals were
culled and quantitative RT-PCR was carried out on nasal
mRNA. We did not detect changes in baseline PD or the
effect of amiloride at any time-point (Table 2), nor any
reduction in αENaC mRNA (Figure 11). Thus, despite
ensuring prolonged contact time of asODN/GL67 com-
plexes with the nasal epithelial cells, transfection effi-
ciency was variable and likely insufficient to reduce ENaC
expression.
Discussion
We have assessed the transfection efficiency and efficacy
of small (approximately 20 bp) nucleic acids (siRNA and
antisense DNA) complexed to GL67 in conducting airway
epithelium in vivo. In general, uptake of small oligonucle-
otides was inefficient and although mRNA levels were
reduced, we could not reduce protein levels or ENaC func-
tion. This study suggests that although siRNAs and
asODNs can be developed to inhibit gene expression in
culture systems and certain organs in vivo, barriers to
nucleic acid transfer in airway epithelial cells seen with
large DNA molecules also affect the efficiency of in vivo
uptake of small nucleic acid molecules.
It is unlikely that alteration in nucleic acid size alone will
result in improved airway nucleic acid transfer. We sug-
gest, that the asODN and siRNA-based strategies may not
be successful in conducting airway epithelium, until
nucleic acid transfer is optimised further.
Interestingly, the intracellular distribution of asODN and
siRNA following in vitro transfection into epithelial cells
was very different, with asODN-lipoplexes accumulating
rapidly in the nucleus while siRNA-lipoplexes were seen
as a diffuse staining in the cytoplasm. For asODN this dis-
tribution was independent of nucleotide sequence, and
has also recently been seen in other cell lines, such as
A549 and HEK293 cells (Chris Kitson, GlaxoSmithKline,
personal communication). To the best of our knowledge,
we show, for the first time, that the respective localisations
in vitro are consistent with the presumed sites of action of
each of the molecules in inhibiting gene expression [23].
Various cationic lipids and polymers have been assessed
for gene transfer to the airways, but information on a
"best buy" non-viral transfer agents for small nucleic acid
delivery does not currently exist. In our hands, GL67 has
been most efficient for airway gene transfer and we have
Table 2: Nasal potential difference measurements in mouse nasal epithelium after perfusion with ENaC antisense DNA
Baseline PD (mV) Amiloride effect (∆mV)
Day Control asODN ENaC asODN Control asODN ENaC asODN
Pre Post Pre Post Pre Post Pre Post
1 15.7 (1.8) 16.3 (1.6) 15.1 (1.8) 20.4 (2.1) -14.3 (1.8) -9.1 (1.3) -14.6 (1.9) -9.7 (1.4)
2 16.9 (2.3) 17.2 (1.7) 16.0 (1.2) 16.3 (2.0) -15.7 (2.3) -13.7 (1.6) -14.8 (1.4) -12.1 (1.3)
3 16.8 (1.9) 17.0 (1.9) 18.0 (1.9) 16.1 (0.9) -12.1 (1.5) -13.0 (2.0) -14.8 (1.4) -12.6 (1.3)
n = 8–10/group. Data are expressed as mean (SEM)
PD = nasal potential difference
Pre = measurements at least 7 to 10 days before administration of control or ENaC asODNs
Post = measurements at the indicated time-points after administration of control or ENaC asODNs.Respiratory Research 2006, 7:26 http://respiratory-research.com/content/7/1/26
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assessed its safety in phase 1 trials in normal volunteers
and CF patients [20,21]. Here, we assessed the efficacy for
GL67 to delivery asODN and siRNA to the airways. In vivo,
siRNA-lipoplexes were found predominantly associated
with alveolar macrophages, whereas asODNs were, as has
been reported previously, associated with pneumocytes.
The reasons for this difference in cellular distribution is
currently unclear, but may relate to differences in RNA
versus DNA-lipoplex properties. Small differences in over-
all complex structure may for example alter the surface
charge slightly, which in turn may affect cell uptake.
Zhang and co-workers recently described administration
of "naked" biotin-labelled siRNA to the lung and reported
diffuse staining in airways and parenchyma [24]. We were
unable to detect any signal after administration of
"naked" FITC-labelled siRNA in the lung (data not
shown). This may in part reflect different detection limits
of these methods (FITC versus biotin-streptavidin) in the
lung, possibly due to high auto-fluorescence of lung tis-
sue. We speculate that the differences in cellular distribu-
tion of asODN in vitro (mainly nuclear) and in vivo
(mainly cytoplasmic) may be due to differences in the
proliferation status of the transfected cells. M1 cells repli-
cate rapidly, whereas the majority of pneumocytes are ter-
minally differentiated non-dividing cells. The nuclear
membrane is likely to present a significant barrier to ODN
uptake in vivo.
The inefficient and variable degree of transfection of the
airway epithelium was also reflected in the experiments
testing inhibition of gene expression. In the airway epithe-
lium of K18-lacZ transgenic mice the administration of
lacZ asODN significantly reduced βgal mRNA 72 and 96,
but not 48 hours, after transfection. In contrast, following
lacZ siRNA transfection lacZ mRNA levels were signifi-
cantly reduced 48 hours after transfection. The delayed
response of asODNSs, may be due to the different sites
and modes of action. In contrast to mRNA there was no
reduction in βgal protein at any time point tested. There
are a number of possible explanations. The predicted half-
life of βgal protein is 20 hours. Harvesting lungs 48 hours
after transfection should, therefore, have allowed a reduc-
tion in protein expression to be seen. However, the half-
life of βgal protein in vivo may be longer than 20 hours,
reducing the likelihood of detecting a significant change
in protein levels during the time course of these experi-
ments. In addition, we cannot exclude a non-linear
response between protein amounts and enzymatic activ-
ity, which may require a substantial reduction in protein
before any changes in enzymatic activity can be seen.
Finally, even with the relatively large numbers studied, we
were only powered to detect a protein reduction of 60%
or more.
Recently several studies described the successful use of
siRNA to inhibit pulmonary influenza virus and respira-
tory syncytial virus infections [25-27] using intravenous
(IV) or intranasal (IN) administration of plasmid DNA
encoding the siRNA or IV plus IN administration of
siRNA. These studies did not specifically assess the effects
of RNA interference in difficult to transfect conducting air-
way epithelial cells, but looked at global anti-viral
responses in the lung. To the best of our knowledge effi-
cacy of RNAi in airway epithelium has not been studied
yet.
We tried to improve transfection efficiency by prolonging
contact time with the airway epithelial cells. For practical
reasons this necessitated a change to the nose. Despite
this, we could not detect any intracellular fluorescent sig-
nal after administration of FITC-labelled siRNA/GL67
complexes and only a low and highly variable signal of
asODN/GL67 complexes. Importantly, the overall trans-
fection efficiency of nasal and lung airway epithelial cells
was identical, despite anatomical differences, lending
credit to using the nasal epithelium as a surrogate for air-
way nucleic acid transfer.
Despite using antisense ODNs that reduced αENaC
mRNA by up to 60% in vitro, results consistent with other
gene targets in our hands, these did not reduce ENaC
mRNA or protein function in murine nasal epithelium in
vivo. The reported half-life of the ENaC protein varies and
appears to be cell-type specific, but is of the order of 40–
120 min in cultured cells [28] and 3–4 hours in Xenopus
oocytes [29]. We know of no data for the murine airways.
In vitro screening of ENaC asODN in M1 cells Figure 10
In vitro screening of ENaC asODN in M1 cells. M1 cells 
were transfected with 5 different αENaC asODN and a con-
trol ODN complexed to Lipofectamine 2000. Forty-eight 
hours after transfection mRNA was extracted and αENaC 
mRNA was quantified. Data are presented as mean +/- SEM. 
** indicates p < 0.01 and *** = p < 0.001 when compared to 
control, n = 6/group.
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Thus, although the stability of the protein may play a role,
we suggest that poor transfection is more likely the reason
for the lack of effect.
The efficiency of siRNA and antisense inhibition is
sequence dependent and though some attempts have
been made to develop computer-assisted design of these
types of molecules extensive biological testing is still
required. The LacZ siRNAs described in this study were
developed using first generation design guidelines that
focused on the overall nucleotide composition and distri-
bution (50:50 AU:GC ratio, with approximately equal dis-
tribution of pyrimidines and purines throughout the
molecule). These siRNAs were analyzed prior to the devel-
opment of second-generation guidelines that focus on
more mechanistically relevant features of siRNAs, particu-
larly a nucleotide composition that favours asymmetri-
cally loading of siRNAs into the ribonucleoprotein
complex that mediates RNAi. Using the first generation
guidelines 3 out of 10 siRNAs mediated a significant
degree of silencing. In our experience this proportion of
effective siRNAs and asODNs reflected the success rate
seen for the design of siRNAs against most transcripts
using first generation guidelines.
A key development in improving small nucleic acid deliv-
ery in vivo, particularly of asODNs, has been modification
of the molecules or their delivery agent to improve their
stability in biological fluids. Neither asODN nor siRNA
stability has been studied in the context of the extracellu-
lar lung environment in humans, though Templin et al
nebulised asODN into the murine lung and reported a
half-life of >20 hours [30]. The airway surface liquid (ASL)
lining the conducting airways is important for host
defence and contains numerous anti-microbial peptides
[31]. Collection of unperturbed ASL in human lung is
impossible and broncho-alveolar lavages (using compar-
atively large volumes) lead to dilution of ASL compo-
nents. Although exhaled breath condensate (EBC), which
can be collected non-invasively and consists of condensed
water and microdroplets, containing volatile and non-vol-
atile compounds representing ASL from the lower respira-
tory tract [32,33], may not mimic all aspects of ASL, it goes
some way towards assessing the stability of small nucleic
acid in the human lung. Importantly, stability of asODNs
and siRNAs in EBC from inflamed lungs of CF patients
was similar to non-CF patients. These data support previ-
ously published stability data for second-generation
asODN, [where one of the non-bridging oxygen atoms in
the phosphodiester bond is replaced with sulphur (phos-
porothioation)], and the addition of 2' O-methylated
RNA residues increase nuclease resistance, and also sup-
port the apparent nuclease stability of siRNA even in the
absence of chemical modification. We did not assess sta-
bility of GL67/siRNA or asODN complexes, because it has
previously been shown that lipid complexing further
increases nuclease stability of oligonucleotides [34].
Conclusion
In summary, gene silencing targeted to conducting airway
epithelial cells is currently inefficient, likely due to the rel-
atively poor transfection efficiency of airway cells with
siRNA and asODN lipid complexes. Techniques for small
nucleic acid transfection are needed if the in vitro promise
of these molecules is to be translated to airway epithelial
cells in vivo.
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